TABLE 4.
Comparison of incidence and type of neurologic manifestations in published case series.
| Present Study | Xiong | Romero‐Sánchez | Pinna | Chen | Karadaş | Mao | Varatharaj | Helms | Benussi | Paterson | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of patients enrolled | 901 | 917 | 841 | 650 | 274 | 239 | 214 | 153 | 58 | 56 | 43 |
| Number of subjects with neurologic symptoms, N (%) | 272 (30.2) | 39 (4.2) | 483 (57.4) | 50 (7.7) | 78 (28.4) | 83 (34.7) | 78 (36.4) | 153 (100) | 49 (84.4) | 56 (100) | 43 (100) |
| Geographical location | Italy | China | Spain | US | China | Turkey | China | UK | France | Italy | UK |
| Monocentric vs Multicentric | Mono‐ | Multi‐ | Multi‐ | Mono‐ | Mono‐ | Mono‐ | Multi‐ | Multi‐ | Mono‐ | Mono‐ | Multi‐ |
| Retrospective vs Prospective | Retro‐ | Retro‐ | Retro‐ | Retro‐ | Retro‐ | Prospect‐ | Retro‐ | Prospect‐ | Retro‐ | Retro‐ | Retro‐ |
| Cohort selection | Unselect* | Unselect* | Unselect* | Unselect* | Unselect* | Select^ | Unselect* | Select§ | Select° | Select§ | Select§ |
| Mental confusion/dizziness, N (%) | 61 (6.8) | 25 (2.7) | 165 (19.6) | 30 (4.6) | 48 (17.5) | 39 (16.3) | 52 (24.3) | 39 (25.5) | 26 (44.8) | No data | No data |
| Stroke, N (%) | 53 (5.9) | 10 (1.1) | 14 (1.7) | 10 (1.5) | No data | 9 (3.8) | 6 (2.8) | 74 (48.4) | 2 (3.4) | 43 (76.8) | 8 (18.6) |
| Dysgeusia/anosmia, N (%) | 82 (9.1) | No data | 93 (11.1) | 8 (1.2) | No data | 34 (14.2) | 23 (10.7) | No data | No data | No data | No data |
| Syncope, N (%) | 81 (9.0) | 3 (0.3) | 5 (0.6) | No data | No data | No data | No data | No data | No data | No data | No data |
| Seizures, N (%) | 19 (2.1) | 0 (0) | 6 (0.7) | 13 (2.0) | No data | 0 (0) | 1 (0.5) | 1 (0.7) | No data | 7 (12.5) | No data |
| Headache, N (%) | 39 (4.3) | 2 (0.2) | 119 (14.1) | 12 (1.8) | 31 (11.3) | 64 (26.8) | 28 (13.1) | No data | No data | No data | No data |
| Encephalitis, N (%) | 5 (0.6) | No data | 1 (0.1) | No data | No data | No data | No data | 7 (4.6) | 1 (1.7) | 0 (0) | 9 (20.9) |
| Psychomotor agitation, N (%) | 26 (2.9) | No data | 69 (8.2) | No data | No data | No data | No data | 23 (15.0) | 40 (69.0) | No data | No data |
| Post‐infective disease, N (%) | 7 (0.8) | No data | 1 (0.1) | 0 (0) | No data | 1 (0.4) | No data | 4 (2.6) | No data | 0 (0) | 18 (41.9) |
| Skeletal muscle injury, N (%) | No data | 2 (0.2) | 108 (12.8) | 6 (0.9) | No data | No data | 23 (10.7) | No data | No data | No data | No data |
Xiong W, et al. Neurology 2020; 95: e1479–e1487; Romero‐Sánchez CM, et al. Neurology 2020; 95: e1060–e1070; Pinna P, et al. J Neurol Sci 2020; 415: 116969; Chen T, et al. BMJ 2020; 368: m1091; Karadaş Ö, et al. Neurol Sci 2020; 41: 1991–1995; Mao L, et al. JAMA Neurol 2020; 77: 683–690; Varatharaj A, et al. Lancet Psychiatry 2020; 7: 875–882; Helms J, et al. N Engl J Med 2020; 382: 2268–2270; Benussi A, et al. Neurology 2020; 95: e910–e920; Paterson RW, et al. Brain 2020; 143: 3104–3120.
Unselected: the study included all subjects admitted to the hospital with a rhino‐pharyngeal swab that tested positive for SARS‐CoV‐2; ^ selected: the study included only patients able to communicate; § selected: the study included only patients with neurologic disturbances at admittance; ° selected: the study included only patients admitted to Intensive Care Unit.